Japan's pharmaceutical sector outperformed, and Otsuka Holdings drew positive focus due to Voyxact phase 3 data

Overview

This report is a pharmaceutical sector weekly note released by J.P. Morgan's Japan equity research team, covering Japanese domestic pharmaceutical sector performance, company events, valuation, catalyst calendar, earnings calendar, and U.S. prescription volume (TRx) tracking for major medicines during the period June 29 to July 3. The report highlights that the Japanese pharmaceutical sector rose 3.7% over the week, outperforming TOPIX's 2.6%, and attributes part of the sector's relative strength to capital rotating into pharmaceuticals after a retreat in AI and semiconductor-related stocks.

Core views

The core view is that short-term performance in the Japanese pharmaceutical sector has improved, and Otsuka Holdings' Voyxact data constitute an important positive catalyst. The 24-month top-line results of Voyxact phase 3 in the VISIONARY trial for IgA nephropathy showed that although no quantitative data were disclosed, Otsuka Holdings estimated improved eGFR versus baseline, indicating annualized renal-function decline is constrained near normal progression rates. The report expects market expectations for Voyxact peak sales to be revised upward and sentiment toward Otsuka Holdings to become more constructive.

Analysis framework

The report uses a framework combining weekly market performance, company-event tracking, valuation comparison, catalyst calendar, earnings calendar, and prescription-volume data. The market-performance portion compares weekly, 1-month, 3-month, 6-month, and year-to-date performance of the Japanese pharmaceutical sector, TOPIX, and selected stocks. The valuation section uses J.P. Morgan estimates and Bloomberg consensus data. The prescription-volume section tracks U.S. TRx for major medicines of multiple Japanese pharmaceutical firms.

Methodology notes

• Market performance comparisonSector versus benchmark relative performance

  By comparing the pharmaceutical sector and individual stocks with TOPIX over different time windows, determine sector fund flows and relative strength.

  The report shows the pharmaceutical sector rose 3.7% for the week, above TOPIX's 2.6%, but performance over 3 months and 6 months remained weaker than TOPIX, indicating a short-term rebound alongside medium-term relative weakness.

• Clinical catalyst analysisPhase 3 read-through

  Use key drug clinical trial results to infer commercial expectations and changes in company sentiment.

  The Voyxact VISIONARY 24-month phase 3 results are viewed as a positive catalyst for Otsuka Holdings, with the core rationale being improved eGFR and controlled deterioration of renal function.

• Prescription-volume trackingTRx monitoring

  Use total U.S. TRx to observe commercialization trends and competitive positioning of key medicines.

  The report lists TRx charts of key medicines and competitors for companies including Takeda, Astellas, Chugai, Otsuka, Sumitomo Pharma, and Shionogi.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Otsuka Holdings (4578.T)

  Core focus company

  Strengths

  Voyxact phase 3 results show improved eGFR versus baseline, potentially prompting the market to raise peak-sales assumptions; six-month and year-to-date price gains of 27.4% are relatively strong versus the Japanese pharmaceutical sector.

  Weaknesses

  The company did not disclose quantitative data, so clinical efficacy and commercial value still require further detailed confirmation.

  Comparison

  Weekly gain of 3.7%, matching the Japanese pharmaceutical sector and above TOPIX's 2.6%; six-month performance is clearly stronger than the sector's -0.5%.

  Risks

  Voyxact full data may underperform expectations, regulatory progress may be delayed, peak sales could be overestimated, and competition from peer therapies could intensify.

• Japan Pharmaceutical Sector

  Covered sector

  Strengths

  Rose 3.7% in the week and outperformed TOPIX, benefiting from fund inflows as AI and semiconductor-related stocks corrected.

  Weaknesses

  down 9.7% over three months and -0.5% over six months, with medium-term performance still weaker than TOPIX.

  Comparison

  Outperformed TOPIX on a weekly basis, but lagged TOPIX over both 3-month and 6-month windows.

  Risks

  Fund-rotation could reverse, company clinical or regulatory events may disappoint, and valuation rerating may lack earnings support.

• Sumitomo Pharma (4506.T)

  Weekly rebound stock

  Strengths

  Weekly gain of 7.8%, among the strongest performers among listed stocks in the report.

  Weaknesses

  Had a pronounced pullback in prior months, and six-month and year-to-date performance is -32.8%.

  Comparison

  The rebound magnitude was higher than both the pharmaceutical sector and TOPIX short term, but medium-term performance remains clearly weak.

  Risks

  The rebound may largely reflect dead-cat bounce recovery; if fundamental improvement is insufficient, persistence is uncertain.

Key data

• Japanese pharmaceutical sector weekly gain3.7%The measurement window is from June 29 to July 3, 2026, and outperformed TOPIX's 2.6%.
• TOPIX weekly gain2.6%Used as the Japanese equity benchmark for relative performance comparison.
• Sumitomo Pharma weekly gain7.8%One of the strongest weekly performers in the covered stocks; the report says it rebounded after a sharp decline over prior months.
• Otsuka Holdings weekly gain3.7%Same as the pharmaceutical sector's weekly gain; the company reported Voyxact phase 3 results.
• Otsuka Holdings six-month gain27.4%Strong performance among covered Japanese pharmaceutical stocks, second only to Santen Pharmaceutical at 35.9%.
• Japanese pharmaceutical sector three-month performance-9.7%TOPIX was 11.5% in the same period, showing the sector still significantly underperformed in the medium term.
• Otsuka Holdings valuation-related growth metricsFY27-30 EPS CAGR 12.6%, FY27-30 OP CAGR 12.4%From the report's Japanese pharmaceutical sector valuation table.

Impact & implications

In the near term, funds rotated from AI and semiconductor-related stocks into the pharmaceutical sector after those areas corrected, supporting the sector's weekly outperformance. For Otsuka Holdings, the Voyxact phase 3 data could lift market expectations for peak sales in the IgA nephropathy indication and improve investor views on the company's R&D pipeline and medium-term growth. However, the report does not disclose quantitative Voyxact data, so market reaction will still depend on subsequent full-data delivery, regulatory path, and confirmation of commercialization assumptions.

Risks

• The lack of quantitative disclosure in Voyxact phase 3 means the market could overestimate its clinical or commercial value.
• The apparent capital inflow from AI and semiconductor-related stock weakness may be a temporary rotation, and pharmaceutical-sector relative strength may not persist.
• The Japanese pharmaceutical sector remains weaker than TOPIX over 3-month and 6-month windows, indicating that the medium-term trend is not yet fully recovered.
• Drug regulatory approvals, PDUFA dates, clinical conferences, and prescription-volume changes could all cause stock-level volatility.
• Currency moves may affect operating profit or business profit for multiple Japanese pharmaceutical companies.

What to watch

• Whether Otsuka Holdings subsequently discloses more complete quantitative phase 3 data for Voyxact.
• Whether the market revises upward peak sales assumptions for Voyxact in IgA nephropathy.
• Whether the July 29 advisory committee meeting on daremio cel BLA and the August 22 PDUFA date remain in place.
• The subsequent impact of Chugai Pharmaceutical's KRAS G12C inhibitor divarasib phase 3 results.
• Whether the Japanese pharmaceutical sector continues to outperform TOPIX, and whether funds keep rotating from AI and semiconductor-related stocks into defensive healthcare.
• U.S. major-drug TRx trends, especially for medicines from Otsuka, Takeda, Astellas, Chugai, and Sumitomo Pharma.